Neurodegenerative diseases are increasing in number, given that the general global
population is becoming older. They manifest themselves through mechanisms that are not …

The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a
double effect: early on during the onset of the immune attack and later for the CNS self …

The identification of physical interactions between drug candidate compounds and target
biomolecules is an important process in drug discovery. Since conventional screening …

Virus-infected cells and cancers share metabolic commonalities that stem from their
insatiable need to replicate while evading the host immune system. These similarities …

Neuroimmunological diseases and their treatment compromise the immune system, thereby
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …

Background Patients who develop relapsing-remitting multiple sclerosis (MS) present with a
first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 …

Background The mechanism of action of oral cladribine, recently licensed for relapsing
multiple sclerosis, is unknown. Objective To determine whether cladribine depletes memory …

Background On the basis of various clinical and MRI measurements, the phase 3 Cladribine
Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by
inflammation and demyelination for which there is currently no cure; therefore, the aim of …

Whereas drugs used for maintenance/escalation therapy do not maintain their beneficial
effect after cessation of therapy, some new highly effective therapies can show prolonged …